Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome

Bone Marrow Transplantation

Volumn 46, Issue 4, 2011, Pages 502-509

  Hilgendorf, I ^a   Wolff, D ^a,d   Gromke, T ^b   Trenschel, R ^b   Elmaagacli, A H ^b   Pichlmeier, U ^c   Junghanss, C ^a   Freund, M ^a   Beelen, D W ^b   Casper, J ^a,e  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MEDAC GMBH   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Clinic Oldenburg   (Germany)

Author keywords

haematopoietic stem cell transplantation; myelodysplastic syndrome; reduced toxicity conditioning; TBI; treosulfan

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; OPIATE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ANALGESIA; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; INTERMETHOD COMPARISON; MALE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; SURVIVAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; COMORBIDITY; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 79953706001     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.153     Document Type: Article

References (20)

1. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood2004; 103: 725-731. (Pubitemid 38140111)
2. Casper JK, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L et al. Allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010 (e-pub ahead of print).
3. Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haemato-poietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008; 142: 284-292. (Pubitemid 351987321)
4. Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplantation 2006; 37: 339-344. (Pubitemid 43250466)
5. Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007; 39: 389-396. (Pubitemid 46487303)
6. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007; 48: 2352-2359. (Pubitemid 350258301)
7. Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998; 71: 94-98. (Pubitemid 28492400)
8. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103. (Pubitemid 34264036)
9. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplan-tation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-968. (Pubitemid 39038014)
10. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
11. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
12. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247-254. (Pubitemid 19152518)
13. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008; 5: 49-59.
14. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246-255.
15. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004. (Pubitemid 35001229)
16. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodys-plastic syndromes or secondary acute leukemia. J Clin Oncol 2009; 28: 405-411.
17. Nemecek ER, Sorror ML, Doney KC, Scott BL, Kovacsovics TJ, Maziarz RT et al. A regimen of treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation (HCT) for high-risk hematologic malignancies is associated with low treatment-related mortality. Blood 2008; 112: 1029 (ASH Annual Meeting Abstracts 2994).
18. Beelen DW, Gromke T, Trenschel R, Hilgendorf I, Wolff D, Elmaagacli AH et al. Treosulfan compared to total body irradiation-based preparative regimens before allogeneic stem cell transplantation for acute myeloid leukemia: a retrospective long-term study. Blood 2008; 112: 748 (ASH Annual Meeting Abstracts 2149).
19. Ruutu T, Beelen DW, Finke J, Holowiecki J, Uharek L, Kienast J et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic haematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Bone Marrow Transplantation 2009; 43: 556 (Suppl 1) (abstract O300).
20. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-inten-sity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584. (Pubitemid 351264351)